Enzon and Viskase Announce Amendment to Merger Agreement

Core Points - Enzon Pharmaceuticals and Viskase Companies have amended their merger agreement, with Viskase merging into a subsidiary of Enzon in an all-stock transaction, resulting in Viskase stockholders owning 55% and Enzon stockholders owning 45% of the combined company [1][2][7] Summary by Sections Merger Agreement - The amendment reflects recent operational developments at Viskase and its expected near-term operations [1] - The merger will maintain Enzon's net operating losses and other tax benefits for the combined company [3] - The amendment was approved by the independent directors of both companies and their respective Boards of Directors [4] Financial Adjustments - The exchange ratio for Viskase stockholders has been adjusted so they will own 55% of the combined company [7] - Enzon will conduct a 1 for 100 reverse stock split prior to the merger [7] - The minimum cash requirement for Enzon at the closing of the merger has been reduced [7] Company Profiles - Enzon Pharmaceuticals is positioned as a public company acquisition vehicle, aiming to become an acquisition platform [5] - Viskase Companies produces non-edible casings for processed meat products and operates nine manufacturing facilities globally, selling products in nearly one hundred countries [8]